RAPP — Rapport Therapeutics Inc. price, chart and key statistics

Price data

Price

$29.37

YTD price return

-3.20%

YTD total return

-3.20%

Next earnings

Nov 5, 2026

Market cap

1.4B2024-06 47.6M2026-10 1.4B+2859.7% over the window

Enterprise value

943.8M

Shares outstanding

48M2023-12 4.2M2026-06 48M+1050.3% over the window

52W low

$23.75

52W high

$52.93

From 52W high

-44.51%

From 52W low

+23.66%

52W range

19%

Volume

Rel volume

11.95×

30D volume

685.9K

30D $ vol

22.7M

Fundamentals

EPS (ttm)

-$3.052023-12 -$23.102026-06 -$3.05-86.8% over the window

FCF (ttm)

-97.1M2023-12 -28.8M2026-06 -97.1M+237.1% over the window

FCF/share

-$2.022023-12 -$6.912026-06 -$2.02-70.7% over the window

Book value/share

$8.812023-12 -$6.152026-06 $8.81-243.4% over the window

ROE

-32.43%2024-12 -25.6%2026-06 -32.4%+26.5% over the window

ROA

-29.88%2023-12 -22.4%2026-06 -29.9%+33.5% over the window

Current ratio

15.722023-12 17.142026-06 15.72-8.3% over the window

Growth (CAGR, ttm) · 10Y

Shares

+31.48%2025-06-30 → 2026-06-3036.5M → 48M (+31.5% total)+165.98%2023-12-31 → 2026-06-304.2M → 48M (+1050.3% total)n/an/a

Per-share growth (CAGR, ttm) · 10Y

Book value/share

+22.11%2025-06-30 → 2026-06-30$7.22 → $8.81 (+22.1% total)n/an/an/a

Price

+11.13%2025-10-20 → 2026-10-20$26.43 → $29.37 (+11.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+15.68%2024-06-07 → 2026-10-20$20.80 → $29.37 (+41.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/an/a

Total return

+11.13%2025-10-20 → 2026-10-20$26.43 → $29.37 (+11.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.68%2024-06-07 → 2026-10-20$20.80 → $29.37 (+41.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/an/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

-9.6×2024-06 -1.372026-10 -10.27+650.6% over the window

Fwd P/E

-5.7×

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

3.3×2024-06 -1.202026-10 3.33-377.4% over the window

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

-6.89%2024-12 -10.4%2026-06 -4.9%-53.2% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 48.0M ÷ 36.5M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-31.48%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-31.48%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($415M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-31.48%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($1.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

0.00%2024-12 0.0%2026-06 0.0%

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($1.4B). Same caveat as the cash buyback yield.

0.00%2024-12 0.0%2026-06 0.0%